- Home
- INDP vs CANF Comparison
INDP vs CANF Comparison
Compare INDP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- CANF
- Stock Information
- Founded
- INDP 2000
- CANF 1994
- Country
- INDP United States
- CANF Israel
- Employees
- INDP N/A
- CANF N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- CANF Health Care
- Exchange
- INDP Nasdaq
- CANF Nasdaq
- Market Cap
- INDP 10.2M
- CANF 14.4M
- IPO Year
- INDP N/A
- CANF N/A
- Fundamental
- Price
- INDP $0.94
- CANF $1.48
- Analyst Decision
- INDP Strong Buy
- CANF Strong Buy
- Analyst Count
- INDP 2
- CANF 2
- Target Price
- INDP $8.50
- CANF $14.00
- AVG Volume (30 Days)
- INDP 25.8K
- CANF 1.2M
- Earning Date
- INDP 11-12-2024
- CANF 12-31-2024
- Dividend Yield
- INDP N/A
- CANF N/A
- EPS Growth
- INDP N/A
- CANF N/A
- EPS
- INDP N/A
- CANF N/A
- Revenue
- INDP N/A
- CANF $667,000.00
- Revenue This Year
- INDP N/A
- CANF $409.56
- Revenue Next Year
- INDP N/A
- CANF N/A
- P/E Ratio
- INDP N/A
- CANF N/A
- Revenue Growth
- INDP N/A
- CANF N/A
- 52 Week Low
- INDP $0.84
- CANF $1.29
- 52 Week High
- INDP $3.10
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- INDP 40.51
- CANF 35.58
- Support Level
- INDP $0.94
- CANF $1.30
- Resistance Level
- INDP $1.01
- CANF $1.72
- Average True Range (ATR)
- INDP 0.06
- CANF 0.18
- MACD
- INDP 0.00
- CANF -0.01
- Stochastic Oscillator
- INDP 28.24
- CANF 17.92
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).